Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P15121
UPID:
ALDR_HUMAN
Alternative names:
Aldehyde reductase; Aldose reductase
Alternative UPACC:
P15121; B2R8N3; Q5U031; Q6FGA4; Q6ICP2; Q9BS21; Q9UCI9
Background:
Aldo-keto reductase family 1 member B1, also known as Aldose reductase, plays a pivotal role in the NADPH-dependent reduction of carbonyl-containing compounds to alcohols. It targets a broad spectrum of substrates, including endogenous metabolites like aromatic aldehydes, ketones, and xenobiotics. This enzyme is crucial in the polyol pathway, converting glucose to sorbitol under hyperglycemic conditions, and is involved in the detoxification of dietary and lipid-derived unsaturated carbonyls.
Therapeutic significance:
Understanding the role of Aldo-keto reductase family 1 member B1 could open doors to potential therapeutic strategies.